Get 50% off with the coupon code COUPON50
6-Hour Virtual Seminar

6-Hour Virtual Seminar on Establish a Compliant Medical Device Post Market Surveillance and Complaint Handling System

John E Lincoln Instructor:
John E Lincoln 
Tuesday, May 27, 2025
10:00 AM PDT | 01:00 PM EDT
6 Hours
Webinar ID: 502955

More Trainings by this Expert

Price Details
Live Webinar
$545 One Attendee
$745 Corporate Live
Recorded Webinar
$595 One Attendee
$945 Corporate Recorded
Combo Offers
Live + Recorded
$912 $1140 Live + Recorded
Corporate (Live + Recorded)
$1352 $1690 Corporate
(Live + Recorded)

Live: One Dial-in One Attendee

Corporate Live: Any number of participants

Recorded: Access recorded version, only for one participant unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)

Corporate Recorded: Access recorded version, Any number of participants unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)

Overview:

This webinar will examine Section 522 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which require manufacturers to conduct postmarket surveillance at the time of approval or clearance or at any time thereafter of certain class II or class III devices. Section 522 is implemented in 21 CFR 822.

This formal postmarket surveillance is the active, systematic, scientifically valid collection, analysis, and interpretation of data or other information about a marketed device. A more generalized "post market surveillance" / complaint handling is also a requirement under the device CGMPs, 21 CFR 820, -.100 - CAPA, and -.198 - Complaints. Data collected under post-market surveillance helps to address important public health questions on the safety and effectiveness of a device, often resulting in improvements in device design and manufacture.

Why should you Attend:
Global companies must meet US FDA 21 CFR 820 (The QSR) requirements in order to sell such devices in the US, no matter where they are manufactured. These companies must pass FDA compliance inspections (audits) to 21 CFR 820. One of the key components of these device CGMPs in addrssing post-market use issues and complaints / CAPA.

The FDA expects companies to have effective programs in place to caputure post-market problems / non-conformances, react to minimize risk to users / patients, and use such data for product imporvement. With certain devices, the FDA mandates such controls. How does failure to comply result in adulterated product, 483 Observations, Warning Letters, and worse. What are key components of a CGMP-compliant post-market surveillance and complaint handling system? Where does Medical Device Reporting / Adverse Events fit into such a system? This six hour seminar will provide suggested and mandated approaches, and the answers to these and other related questions.

Agenda:

  • FD&C Act Section 522
  • 21 CFR 822
  • FDA Guidance Documents' Recommendations
  • Design Contol; Risk Management, and Human Factors / Use Engineering
  • Production and Process Controls
  • CAPA
  • The Risk Management File (ISO 14971) and its role
  • The Use Engineering File (IEC 62366-1) and its role
  • Expected QMS Records

Who Will Benefit:
  • Senior Management
  • Regulatory Affairs
  • Quality Assurance
  • Production
  • R&D and Engineering
  • All Personnel Involved in the U.S. FDA-regulated Medical Device Development, Manufacture, and post market activities. Especially those involved in new medical device / combination product development, non-conformancess and field problems / complaints, line extensions, and incremental product improvements; having to evaluate those changes in light of the DHF / CGMPs, and then document these actions in harmony with the regulations


Speaker Profile
John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide.

John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.


You Recently Viewed

Subscribe to our Newsletter

Subscribe for Compliance Alerts Research Reports Absolutely Free